Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing analysis of patient derived xenograft tissue PIM-084 treated with L-NMMA+alpelisib vs vehicle control

ABSTRACT: RNA sequencing analysis of patient derived xenograft tissue PIM-084 treated with L-NMMA+alpelisib vs vehicle control

PROVIDER: PRJNA1175746 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA sequencing analysis of patient derived xenograft tissue PIM-084 treated with L-NMMA+alpelisib vs vehicle control

Project description:RNA sequencing analysis of patient derived xenograft tissue PIM-084 treated with L-NMMA+alpelisib vs vehicle control

| PRJNA1175745 | ENA

PIM kinase inhibition in HCC xenograft

Project description:PIM kinase inhibition in HCC xenograft

| PRJNA598723 | ENA

PIM kinase inhibition in HCC xenograft

Project description:Human HCC cell line, MHCC-97L, was subcutaneously injected to BALB/c nude mice. Two weeks post injection, mice were randomised to receive vehicle or PIM447 (60mg/kg) by oral gavage three times a week for two weeks. Total RNA was extracted from the tumor xenograft (Vehicle, n=2; PIM447, n=2) and subjected to RNA sequencing. Expression profiling of the tumors between vehicle control and PIM447 treated groups was compared.

2020-06-03 | GSE142871 | GEO

IMPRINTS-CETSA Alpelisib and Buparlisib in MCF-7 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Alpelisib and Buparlisib using TMT 10 plex.

2024-10-23 | PXD056196 | Pride

IMPRINTS-CETSA Alpelisib and Buparlisib in MCF-7 cells, 6h incubation

Project description:IMPRINTS-CETSA data acquisition of MCF-7 cells treated with Vehicle (DMSO), Alpelisib and Buparlisib using TMT 10 plex.

2024-10-23 | PXD056197 | Pride

Expression data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle

Project description:We kept 2 types of primary xenograft models (KURC;Kyoto University Renal Cancer-1,3) derived from human renal cell carcinoma tissues, and 10 mg/kg of temsirolimus or vehicle was intraperitoneally administered.We performed microarray analysis to compare the gene expression profile of temsirolimus-treated primary xenograft tumors with that of vehicle-treated.

2019-12-31 | GSE133446 | GEO

Transcriptome analysis PIM kinase inhibition vs degradation

Project description:PIM kinases have important pro-tumorigenic roles and mediate several oncogenic traits, including cell proliferation, survival, and chemotherapeutic resistance. As a result, multiple PIM inhibitors have been pursued as investigational new drugs in cancer; however, response to PIM inhibitors in solid tumors has fallen short of expectations. We found that inhibition of PIM kinase activity stabilizes protein levels of all three PIM isoforms (PIM1/2/3), and this can promote resistance to PIM inhibitors and chemotherapy. To overcome this effect, we designed PIM proteolysis targeting chimeras (PROTACs) to target PIM for degradation. PIM PROTACs effectively downmodulated PIM levels through the ubiquitin-proteasome pathway. Importantly, degradation of PIM kinases was more potent than inhibition of catalytic activity in inducing apoptosis in prostate cancer cell line models. In conclusion, we provide evidence of the advantages of degrading PIM kinases versus inhibiting their catalytic activity to target the oncogenic functions of PIM kinases.

2023-12-04 | GSE237256 | GEO

DNA methylation data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle

Project description:We kept a primary xenograft models (KURC;Kyoto University Renal Cancer-3) derived from human renal cell carcinoma tissues, and 10 mg/kg of temsirolimus or vehicle was intraperitoneally administered.We performed DNA methylation analysis to compare the methylation profile of temsirolimus-treated primary xenograft tumors with that of vehicle-treated.

2019-12-31 | GSE133444 | GEO

Transcriptomic analysis of Nintedanib, Alpelisib and Nintedanib Alpelisib treated bladder tumors

Project description:Transcriptomic analysis of Nintedanib, Alpelisib and Nintedanib Alpelisib treated bladder tumors

| PRJNA758030 | ENA

Transcriptomic analysis of Nintedanib, Alpelisib and Nintedanib Alpelisib treated bladder tumors

Project description:Transcriptomic analysis of Nintedanib, Alpelisib and Nintedanib Alpelisib treated bladder tumors

| PRJNA904345 | ENA